Compare Cassava Sciences Inc (FLNA) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs MPLX LP — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while MPLX LP trades at $60.15 (market cap $60.12B). The key difference: MPLX LP is far larger — about 1259.1× Cassava Sciences Inc's market cap, and MPLX LP pays a 7.26% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MPLX | |
|---|---|---|
Market Cap | $47.75M | $60.12B |
Sector | Health | Technology |
52-Week High | $4.64 | $60.51 |
52-Week Low | $0.87 | $47.80 |
Enterprise Value | -$34.93M | $85.22B |
Dividend Yield | — | 7.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
MPLX trades at $59.75, up 1.79% today, with a bullish technical signal from moving averages and support near $59. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 and Q2 2026 EPS missed expectations. Recent news highlights a $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) and solid Q2 performance driven by natural gas and NGL volume growth.
Outlook remains positive with a 67.86% analyst buy rating and $61.50 consensus price target, offering potential upside. Key opportunities include fee-based revenue stability and dividend growth, while risks involve higher capital spending and execution challenges on growth projects. The stock presents a balanced profile for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
